Salud financiera de hoja de balance de Addex Therapeutics

Salud financiera controles de criterios 6/6

Addex Therapeutics tiene un patrimonio de los accionistas total de CHF1.1M y una deuda total de CHF0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CHF4.6M y CHF3.5M respectivamente.

Información clave

Ratio deuda-patrimonio

CHF0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CHF3.87m
Patrimonio	CHF1.15m
Total pasivo	CHF3.50m
Activos totales	CHF4.64m

Actualizaciones recientes sobre salud financiera

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Mar 03

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

May 11

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)

Jun 10

Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Mar 07

What Type Of Returns Would Addex Therapeutics'(VTX:ADXN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CHF4.2M) de ADXN superan a sus pasivos a corto plazo (CHF2.9M).

Pasivo a largo plazo: Los activos a corto plazo de ADXN (CHF4.2M) superan a sus pasivos a largo plazo (CHF603.1K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ADXN está libre de deudas.

Reducción de la deuda: ADXN no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ADXN tiene suficiente cash runway para 6 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que ADXN disponga de suficiente cash runway para 7 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Addex Therapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Addex Regains Nasdaq Listing Compliance

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Addex Regains Nasdaq Listing Compliance

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Recent updates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Addex Therapeutics Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024

Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders

New major risk - Shareholder dilution

Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million.

Addex Therapeutics Ltd to Report Q3, 2024 Results on Nov 11, 2024

Co-Founder recently bought CHF911k worth of stock

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Addex Regains Nasdaq Listing Compliance

New minor risk - Profitability

Consensus revenue estimates increase by 31%

Addex Therapeutics Announces Data Published in Brain

New major risk - Market cap size

Second quarter 2023 earnings released: CHF0.04 loss per share (vs CHF0.19 loss in 2Q 2022)

Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

First quarter 2023 earnings released: CHF0.04 loss per share (vs CHF0.15 loss in 1Q 2022)

Addex Therapeutics Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

Insufficient new directors

No longer forecast to breakeven

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

Addex Regains Nasdaq Listing Compliance

Addex Therapeutics Ltd to Report Fiscal Year 2022 Results on Mar 13, 2023

No longer forecast to breakeven

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Consensus revenue estimates fall by 27%

Addex Therapeutics Ltd announced that it has received funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive funding from Armistice Capital LLC

No longer forecast to breakeven

Consensus forecasts updated

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate

Consensus forecasts updated

Addex Therapeutics Ltd Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

No longer forecast to breakeven

Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CHF1.40

Forecast to breakeven in 2024

Addex Therapeutics Ltd Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Addex Therapeutics Ltd Expands Pipeline with Selective M4 Positive Allosteric Modulator Program

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Consensus revenue estimates fall by 64%

Price target decreased to CHF1.40

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2023

Addex Therapeutics Ltd announced that it has received CHF 5.427937 million in funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive CHF 5.427937 million in funding from Armistice Capital LLC

Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: CHF0.11 loss per share (vs CHF0.12 loss in 3Q 2020)

Addex Therapeutics Ltd Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Second quarter 2021 earnings released: CHF0.14 loss per share (vs CHF0.12 loss in 2Q 2020)

Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)

Addex Therapeutics Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia

Consensus forecasts updated

First quarter 2021 earnings released: CHF0.08 loss per share (vs CHF0.16 loss in 1Q 2020)

Consensus revenue estimates increase to CHF3.90m

Full year 2020 earnings released: CHF0.48 loss per share (vs CHF0.56 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?